PTGX News and Press, Protagonist Therapeutics Inc. From 03/22/24

2024-03-22 15:00:00 ET More on the markets Wall Street Lunch: Fed Not Spooked By Recent Inflation SPY: Don't Fall For The Greed SPY: Assessing Economic Risks And Market Trends (Technical Analysis, Rating Downgrade) Investors sell $66B worth of money market fu...

NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on ...

2024-03-14 17:02:13 ET Gainers: Immuneering Corporation ( IMRX ) +133% . Geron Corporation ( GERN ) +81% . Cardlytics ( CDLX ) +37% . Brilliant Earth Group ( BRLT ) +8% . Acacia Research Corporation ( ACTG ) +7% . Losers: ...

Long-term extension (LTE) FRONTIER 2 study demonstrated sustained efficacy and similar safety results from Week 16 to Week 52, consistent with previously reported FRONTIER 1 16-week Phase 2b study The proportion of patients achieving PASI 75, 90 and 100 response rates at Week 16 were maintai...

2024-03-09 13:34:43 ET More on Johnson & Johnson Johnson & Johnson (JNJ) Cowen 44th Annual Health Care Conference (Transcript) Johnson & Johnson: A Clean Bill Of Health Johnson & Johnson: A High-Quality Dividend King Facing Furious Headwinds J...

2024-03-04 12:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications Cash runway extended through Q4 2027[1] Two articles published in the New England Journal of Medici...

2024-02-25 11:37:55 ET Summary Protagonist Therapeutics' stock has experienced significant volatility over the past three years, with multiple setbacks and recoveries. The company's lead drug candidate, Rusfertide, indicated for polycythemia vera, faced a clinical hold from the FD...

- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy - Rusfertide was associated with lower disease-related symptoms in patients with moderate/severe scores at baseline as assess...

JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. NEWARK, CA / ACCESSWIRE / February 7, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or ...